Bill Detail
H.R. 7867
Congress: 119
Title
Infant Formula Safety Modernization Act of 2026
Summary
Infant Formula Safety Modernization Act of 2026 This bill directs the Food and Drug Administration (FDA) to expand requirements for the testing of infant formula and formula manufacturing facilities for pathogens and microorganisms. Current regulations generally require manufacturers to test finished formula products for Cronobacter and Salmonella. The FDA tests manufacturing facilities for these contaminants in regular inspections, but manufacturers are not required to test their own facilities. Within 90 days of the bill's enactment, the FDA must issue a final rule requiring manufacturers to test their facilities and finished formula products for certain pathogens and microorganisms, including Clostridium botulinum (which causes botulism). These regulations must include a recommended frequency for facilities testing, including requirements for testing different areas based on their proximity to formula products. Manufacturers must notify the FDA within one business day of any positive result for one of the specified pathogens or microorganisms in a finished formula product, even if the product is still in the manufacturer’s possession. (Currently, notice is required only if the affected product has left the manufacturer’s facilities.) Manufacturers must also retain records of any positive result (from a test of formula or facilities). The FDA must notify Congress within one business day of receiving notice of a positive test result for a finished formula product, or recommending official corrective action to address the findings of a facility inspection. Finally, the regulations must explicitly require the FDA to enforce consistent inspection and compliance standards for all formula products, including imported products.
Sponsor
Rep. Rosa DeLauro [D-CT-3]
Status
Referred to the House Committee on Energy and Commerce.
Status as of Nov 9, 2026, 3:58 PM · synced 7d ago
Introduced
2026-03-09
Data source mode: congress-gov
Bill Engagement
Infant Formula Safety Modernization Act of 2026 This bill directs the Food and Drug Administration (FDA) to expand requirements for the testing of infant formula and formula man…
Lobbyists on the case
These are cached disclosure mentions, not verified current representation or confirmed event attendance.
- The Smith-free Group, LLC1 filing · 4 lobs
- John Christie2026 Q3The Smith-free Group, LLC · Chief of Staff, Rep. Alma Adams; Leg. Director, Rep. Alma Adams …
- Michael Gaffin2026 Q3The Smith-free Group, LLC · Leg. Director, Sen. Sherrod Brown; Leg. Director, Rep. Rob Andrews …
Limited preview · paid intelligence
Keep the intelligence current—not just this one record.
Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.
Federal Intelligence is $2,500 one-time for three months, or $9,000 for twelve months prepaid, for one named user. Full tracked federal calendar, connected organization/bill/disclosure research, and a private workspace. Fixed terms; no automatic renewal. No demo or scope email is required for standard access.
After verified successful payment, access is activated within one business day and a secure setup link is emailed. Your term starts at activation. These links do not charge you or unlock records. A free alert subscription does not grant full access.